北京商报讯（记者 孟凡霞 周义力）1月30日，国家金融监督管理总局北京监管局发布行政处罚信息公开 表显示，中国信达资产管理股份有限公司北京市分公司因"业务尽职调查不到位，业务风险评估不到 位、审批不审慎，风险加权资产计提有误"等违法违规行为，被处罚款110万元；相关责任人周顺被警告 并处罚款5万元。 ...

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 130 million to 180 million yuan in 2025, recovering from a loss of 96.3764 million yuan in the previous year, primarily due to the recovery of the film market and improved operational management [1] Group 1: Financial Performance - The projected net profit for 2025 is between 130 million and 180 million yuan, indicating a significant turnaround from the previous year's loss [1] - The company attributes this improvement to increased box office revenue driven by a recovering film market [1] Group 2: Business Strategy - The company has strengthened its operational management and diversified its business while focusing on cost reduction and efficiency enhancement [1] - The company has released several films, including "Boonie Bears: Rebooting the Future," "The Legend of the Condor Heroes: The Great Hero," and "The Volunteer Army: Blood and Peace," through its wholly-owned subsidiary Zhejiang Hengdian Film Co., Ltd [1] - Upcoming films such as "Boonie Bears: Year of the Bear," "Racing Life 3," and "Dream of the Galaxy" are scheduled for release during the 2026 Spring Festival [1] - The company has established a short drama brand "Big Horizontal and Small Vertical" to accelerate the development of its short drama business [1]

北京商报讯（记者 孟凡霞 周义力）1月30日，国家金融监督管理总局宁波监管局发布行政处罚信息公开 表显示，温州银行宁波分行因"授信业务管理不到位、员工行为管理不到位、监管统计数据不准确、贷 款风险分类不审慎"等违法违规行为，被处罚款135万元；相关责任人郑宇被警告。 ...

Core Viewpoint - Panda Dairy expects to achieve a net profit attributable to shareholders of 97 million to 112 million yuan for the fiscal year 2025, compared to approximately 102 million yuan in the previous year, indicating stable overall performance [1] Financial Performance - The company's overall performance is expected to remain stable in 2025, supported by growth in subsidiary businesses and effective control of raw material costs [1] - The impact of non-recurring gains and losses on the net profit attributable to shareholders is estimated to be 33 million yuan, primarily due to investment income, government subsidies, and changes in the fair value of trading financial assets [1]

百利天恒表示，报告期内，为加快推进产品管线的研发进度，巩固产品管线的领先优势，早日实现产品 上市以惠及患者，公司持续加大研发投入，导致研发投入同比增幅较大。 北京商报讯（记者 丁宁）1月30日晚间，百利天恒（688506）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年实现归属净利润为-11亿元左右，同比减少129.67%左右。 同时，报告期内，公司与百时美施贵宝（BMS）就iza-bren 的合作顺利推进，全球II/III期关键注册临床 试验IZABRIGHT-Breast01里程碑达成，并收到第一笔2.5亿美元里程碑付款。上年同期，公司收到BMS 就iza-bren合作协议的8亿美元不可撤销、不可抵扣的首付款，公司相应确认相关知识产权收入。报告期 内收入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收 入。 ...

香飘飘表示，公司传统冲泡产品销售旺季集中于春节前，销售窗口期包含当年第四季度部分时段及来年 第一季度部分时段。受 2025 年春节时点提前及2026年春节时点延后的共同影响，2025年第一季度、第 四季度销售窗口期均有所缩短，致使销量出现同比下滑。 北京商报讯（记者 孔文燮）1月30日，香飘飘发布公告称，预计2025年年度实现归母净利润1.02亿到 1.25亿元，同比减少50.59%到59.68%。同时，预计报告期内实现营业收入为29.27亿元左右，与上年同 期相比减少10.95%左右。2025年度业绩下降，主要系传统冲泡产品销售下滑影响。 ...

北京商报讯（记者 李秀梅）近日，相关话题"金晨被曝疑似涉嫌交通肇事逃逸"引发各界关注。1月30 日，"柯桥警方"发布通报表示，1月29日，浙江绍兴市公安局柯桥区分局关注到网传金某在绍兴柯桥涉 嫌交通肇事"顶包"信息后，立即成立专班，开展事故情况复查，调查过程复核等工作。 现基本查明，2025年3月16日中午11时许，金某，徐某青，刘某祎（经核查，三人均为外省籍人员，均 系首次来绍）结伴在绍兴柯桥古镇游玩、购物，其间未就餐。15时07分，金某（持有效驾驶证件）驾驶 沪F牌照黑色越野车，途经柯桥湖塘街道一路段时，为避让路上窜行犬只发生单车事故，造成车内3人 轻微受伤，及驾驶车辆、道路路牌、村居围墙受损。 事故发生后，金某因脸部受伤急于就诊，在刘某祎的陪同下打车离开，直接前往上海一医院检查住院， 由徐某青留在现场报警处置。交警调查中，徐某青谎称自己系驾驶员，民警经初查判断为单车事故，未 发现异常情况，遂按简易程序进行处理。 经调查，徐某青事后未向保险公司实际理赔，不存在骗保事实。 1月30日，金晨发微博表示："由于事发突然，加上当时情绪紧张，助理向交警说明自己是驾驶人，并配 合完成了事故认定。当我手术结束意识恢复后 ...

Core Viewpoint - Changchun Gaoxin (000661) expects a significant decline in net profit for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The increase in research and development expenses is attributed to the advancement of product development in traditional and innovative areas [1] Group 2: Product Development and Sales - The company has launched several new products, including the first domestic innovative biological agent for acute gouty arthritis, Jinbeixin (Fuxin Qibai Dantong) [1] - Efforts are ongoing to promote key products such as Jinbeixin and Meishiya, with a focus on enhancing sales promotion, terminal coverage, and channel penetration [1] Group 3: Market Adaptation and Policy Response - The company successfully included long-acting growth hormone products in the national medical insurance catalog, adapting sales policies and pricing in response to industry policy changes [2] - Adjustments in product sales policies and pricing, along with the arrangement of product delivery schedules, have led to a reduction in related revenue and net profit [2]

赛诺医疗表示，由于营业收入同比预计增长13%至15%，营业成本和管理费用预计同比均小幅增长，以 及销售费用、研发费用及资产减值损失预计同比下降，加之上年同期归属净利润基数较小等多方面因素 共同影响，公司预计本期归属净利润将实现大幅增长。 北京商报讯（记者 丁宁）1月30日晚间，赛诺医疗（688108）发布2025年度业绩预增公告显示，预计 2025年实现归属净利润为4300万元至5000万元，同比增长2767%至3233%。 ...

北京商报讯（记者 丁宁）1月30日晚间，君实生物（688180）发布2025年业绩预告显示，预计2025年实 现归属净利润为-8.73亿元左右，与上年同期相比亏损减少4.08亿元左右，同比亏损减少31.85%左右。 君实生物表示，公司2025年年度归属净利润仍出现亏损，但亏损金额与上年同期相比显著缩窄，主要系 公司持续落实"提质增效重回报"行动方案，商业化能力显著提升的同时不断加强费用管控与资源聚焦。 报告期内，公司在控制费用的同时维持了核心管线的高效推进，正快速推进PD-1/VEGF 双抗（代号： JS207）、EGFR/HER3 ADC（代号：JS212）、PD-1/IL-2融合蛋白（代号：JS213）等多款具有国际市 场竞争力的创新药物的临床试验，并积极探索多种联用方案，以最大程度发挥管线协同作用。 ...